Share Price Increase#
Shares of Pacira BioSciences (NASDAQ:PCRX) increased by 2% to $22.78 in premarket trading on Wednesday.
Activist Investor's Actions#
Activist investor DOMA Perpetual has nominated three new directors to join Pacira’s board and is advocating for the removal of CEO Frank Lee. The investor cites years of poor financial performance as the reason for this push.
Financial Performance Concerns#
DOMA Perpetual highlighted that Pacira’s stock has decreased significantly over the years, falling 56% over the past decade, 68% over the last five years, and 30% during Lee’s time as CEO. This decline raises concerns about the company's ability to grow and succeed in the market.
Strategic Recommendations#
The activist investor argues that Pacira is too small to effectively market its non-opioid surgery pain medication, Exparel. They suggest that the company should consider a formal sale process to enhance its market position. Additionally, DOMA Perpetual criticized the board for approving high executive compensation and moving the company’s headquarters to San Francisco.